SENSEI Miniature Gamma Probe Shows Promise in Prostate Cancer Surgery
Lightpoint Medical has released clinical trial results that support the use of the company's miniature surgical gamma probe, SENSEI, in prostate sentinel lymph node detection. The interim results demonstrate a 100% detection rate of sentinel lymph nodes using SENSEI in minimally invasive and robot-assisted prostate cancer surgery.
The results from the multi-center clinical trial, which involves cancer centers at Hospital del Mar, Barcelona, Spain; Institut Paoli-Calmettes, Marseille, France; and UZ Leuven, Belgium, also indicate that SENSEI performed better than standard rigid gamma probes, as SENSEI found additional pelvic sentinel nodes in anatomically restricted areas that could not be detected by the rigid gamma probe. The final study results, expected in Q1 2022, will provide further insights into the performance differences between SENSEI and rigid gamma probes.
The trial results were presented at the Annual Congress of the European Association of Nuclear Medicine.
The clinical trial results demonstrate the ease of use and performance of SENSEI in prostate cancer surgery and signal potential application in other surgical procedures across major cancer types.
“These clinical trial results demonstrate that the use of SENSEI in prostate cancer surgery dramatically enhances our surgical management of prostate cancer patients and is shown to effectively detect sentinel lymph nodes. We look forward to using SENSEI in more procedures and evaluating the probe in combination with the new targeted imaging agent, 99mTc-PSMA, for direct detection of disease metastasis in pelvic lymph nodes,” said Dr. Lluís Fumadó, Principal Investigator from Hospital del Mar, Barcelona.
“There are active clinical studies at multiple cancer centers evaluating SENSEI in prostate, cervical, and colorectal cancer with studies in lung and endometrial cancer in the pipeline. These positive and highly encouraging results from our multi-center study evaluating SENSEI in prostate cancer surgery demonstrate the ease of use and performance of SENSEI and signal potential application in other major cancer types to detect cancer intra-operatively. All of us at Lightpoint Medical are incredibly grateful to Dr. Lluís Fumadó and the team at Hospital del Mar for leading this study and to all the clinical centers and patients who are working with us,” added Graeme Smith, Lightpoint Medical CEO.